The U.S. regulatory environment for digital assets has never been more promising for the industry. Since the change in administration, the Securities and Exchange Commission (SEC) has committed to stemming what it has...more
9/16/2025
/ Blockchain ,
Class Action ,
Cryptocurrency ,
Digital Assets ,
Enforcement Actions ,
Healthcare ,
Howey ,
Investment Contract ,
Life Sciences ,
Rule 10b-5 ,
Securities Act of 1933 ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act of 1934 ,
Securities Litigation ,
Securities Regulation ,
Securities Tokens ,
Tokenization
Key Points -
- The SEC’s Crypto Task Force acknowledges past hostility toward digital assets and aims to create more sensible regulations.
- Tokenized securities face complex regulatory challenges, including compliance...more
5/28/2025
/ Acquisitions ,
Blockchain ,
Broker-Dealer ,
Corporate Governance ,
Cryptocurrency ,
Digital Assets ,
Energy Sector ,
Financial Institutions ,
Financial Services Industry ,
Healthcare ,
Investment Company Act of 1940 ,
Life Sciences ,
Mergers ,
Private Equity ,
Retail Market ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act of 1934 ,
Securities Fraud ,
Securities Litigation ,
Securities Regulation ,
Securities Tokens ,
Technology
A California state court dismissed a putative securities fraud class action against Uber, as well as certain individuals and underwriters, on the grounds of inconvenient forum, holding that the federal forum selection...more
11/30/2020
/ Choice-of-Law ,
Class Action ,
Dismissals ,
Forum Selection ,
Jurisdiction ,
Securities Act of 1933 ,
Securities Fraud ,
Securities Litigation ,
Securities Violations ,
State Law Claims ,
Uber
On October 8, 2020, the U.S. Court of Appeals for the Ninth Circuit reversed the dismissal of a putative securities fraud class action in a decision that provides additional guidance concerning the standard for pleading loss...more
On June 10, 2020, the Ninth Circuit affirmed the dismissal of a putative securities fraud class action in a potentially significant decision for securities defendants, particularly those in the pharmaceutical, biotech and...more
6/16/2020
/ Biotechnology ,
FDA Approval ,
Food and Drug Administration (FDA) ,
Inflated Projections ,
Medical Devices ,
Pharmaceutical Industry ,
Publicly-Traded Companies ,
Putative Class Actions ,
Scienter ,
Securities Fraud ,
Securities Litigation